Amgen Inc. (AMGN)

NASDAQ: AMGN · IEX Real-Time Price · USD
225.40
-3.01 (-1.32%)
At close: Sep 30, 2022 4:00 PM
225.50
+0.10 (0.04%)
After-hours: Sep 30, 2022 7:32 PM EDT
-1.32%
Market Cap 120.57B
Revenue (ttm) 26.38B
Net Income (ttm) 6.58B
Shares Out 534.93M
EPS (ttm) 11.76
PE Ratio 19.17
Forward PE 12.15
Dividend $7.58 (3.36%)
Ex-Dividend Date Aug 17, 2022
Volume 2,543,475
Open 228.42
Previous Close 228.41
Day's Range 225.17 - 230.00
52-Week Range 198.64 - 258.45
Beta 0.56
Analysts Buy
Price Target 258.18 (+14.5%)
Earnings Date Oct 31, 2022

About AMGN

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment o... [Read more...]

Industry Biotechnology
Founded 1980
CEO Robert Bradway
Employees 24,200
Stock Exchange NASDAQ
Ticker Symbol AMGN
Full Company Profile

Financial Performance

In 2021, Amgen's revenue was $25.98 billion, an increase of 2.18% compared to the previous year's $25.42 billion. Earnings were $5.89 billion, a decrease of -18.87%.

Financial Statements

Analyst Forecast

According to 36 analysts, the average rating for AMGN stock is "Buy." The 12-month stock price forecast is 258.18, which is an increase of 14.54% from the latest price.

Price Target
$258.18
(14.54% upside)
Analyst Consensus: Buy
Stock Forecasts

News

3 Biotech Stocks to Buy and Hold for the Next 10 Years

These drugmakers seem to have a knack for innovation.

Other symbols: EXELVRTX
3 days ago - The Motley Fool

Dow Jones ETF Avoids Bear Market: 4 Stocks in Green

Both the S&P 500 and the tech-heavy Nasdaq Index are in bear market while the Dow Jones in the only of the three main indexes not to have bear market status.

Other symbols: CVXMRKUNH
5 days ago - Zacks Investment Research

The 7 Best Biotech Stocks to Buy

I've written before about how biotech is the biggest technology trend of our kids' generation. Naturally, that means many people are looking for the best biotech stocks to buy.

Other symbols: CRSPEXELIBBIONSMRKTWST
1 week ago - InvestorPlace

Amgen CEO Sees Tougher Sledding for Emerging Biotechs

Amgen Inc. ( AMGN , Financial) CEO Robert Bradway contends that small and mid-sized biotechs may find it much harder to remain independent, a situation that Fierce Pharma reported was exacerbated by new...

1 week ago - GuruFocus

Consumer group says drugmakers abuse U.S. patent system to keep prices high

Makers of the top selling drugs in the United States are costing patients billions of dollars and worsening a drug pricing crisis by abusing the U.S. patent system to stifle competition and inflate pric...

Other symbols: ABBVBMYPFE
2 weeks ago - Reuters

Amgen's new cancer drug faces questions about competition

Amgen Inc.'s AMGN, +0.17% Lumakras, which already has a type of conditional approval to treat lung cancer, produced mixed results in a closely watched clinical trial comparing the drug to docetaxel, a c...

2 weeks ago - Market Watch

Amgen CEO on New Products, M&A, Drug Pricing Legislation

Amgen Inc. Chairman and Chief Executive Officer Robert Bradway discusses the biopharmaceutical company's new products, merger and acquisition strategy, and the impact of US drug pricing legislation on "...

2 weeks ago - Bloomberg Markets and Finance

3 High-Yielding Dividend Stocks That May Hike Their Payouts in the Next 2 Years

These are stocks all income investors should consider buying and holding.

Other symbols: SWKTPR
2 weeks ago - The Motley Fool

Here's who could benefit from Biden's biotech initiative, according to Oppenheimer's Jared Holz

Oppenheimer's Jared Holz on President Biden's cancer initiative and what it means for biotech in the U.S. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Courtney Garcia, Guy Adami and ...

2 weeks ago - CNBC Television

AMGEN ANNOUNCES WEBCAST OF 2022 BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE

THOUSAND OAKS, Calif. , Sept. 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Bank of America Merrill Lynch's 2022 Global Healthcare Conference at 4:55 a.m.

2 weeks ago - PRNewsWire

Amgen (NASDAQ:AMGN) – Here's Why Amgen Shares Are Diving

Amgen, Inc. (NASDAQ: AMGN) shares are trading lower by 4.11% to $237.51 during Monday's pre-market session following FDA approval of Bristol Myers Squibb Co's (NYSE: BMY) plaque psoriasis drug Sotyktu, ...

2 weeks ago - Benzinga

LUMAKRAS® (SOTORASIB) COMBINED WITH VECTIBIX® (PANITUMUMAB) SHOWS CONFIRMED 30% OBJECTIVE RESPONSE RATE IN PATIENTS W...

Phase 1b Results Demonstrate Encouraging Median Progression-Free Survival of 5.7 Months in Difficult-to-Treat Patient Population THOUSAND OAKS, Calif. , Sept. 12, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMG...

2 weeks ago - PRNewsWire

Amgen says Lumakras cuts risk of lung cancer progression by 34%

Amgen Inc's Lumakras pill reduced the risk of disease progression in patients with advanced lung cancer by 34% compared with chemotherapy in a clinical trial, the company said on Sunday.

2 weeks ago - Reuters

LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHAS...

At 1-Year, Progression-Free Survival was 25% for LUMAKRAS Versus 10% for Docetaxel LUMAKRAS Met Key Secondary Endpoint of Objective Response Rate THOUSAND OAKS, Calif. , Sept. 11, 2022 /PRNewswire/ -- A...

2 weeks ago - PRNewsWire

Could This Biosimilar Drug Candidate Be a Winner for Amgen?

Amgen's biosimilar drug is close to stealing away sales from AstraZeneca's rare disease drug called Soliris.

3 weeks ago - The Motley Fool

Cancer-Drug Maker's Solid Position And Successful Drug Record Drive Growth

Cancer-drug maker Amgen solidified its position in a highly competitive market by acquiring its rival Mirati Therapeutics.

Other symbols: BBHCCXIDJDIBBMRTX
3 weeks ago - Investors Business Daily

AMGEN ANNOUNCES WEBCAST OF 2022 MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE

THOUSAND OAKS, Calif. , Sept. 8, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Morgan Stanley's 2022 Global Healthcare Conference at 9:10 a.m.

3 weeks ago - PRNewsWire

AMGEN ANNOUNCES POSITIVE NEW DATA AT EADV 2022 FOR OTEZLA® (APREMILAST)

SPROUT Data Show Otezla Resulted in Significant Improvements in Measures of Moderate to Severe Plaque Psoriasis at Week 16 Compared With Placebo in Children Ages 6-171 DISCREET 16-week Data Demonstrated...

3 weeks ago - PRNewsWire

AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2022

THOUSAND OAKS, Calif. , Sept. 7, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology Annual Congr...

3 weeks ago - PRNewsWire

What's Driving Amgen Stock Higher?

Amgen stock (NASDAQ: AMGN) has seen an 8% rise this year, far better than the broader S&P500 index, which is down 18%.

3 weeks ago - Forbes

7 Dow Stocks With Superior Fundamentals

Today I'm writing about Dow stocks to buy. Seasoned investors are realizing that many of the 30 members of the Dow Jones Industrial Average (DJIA) are now trading at low valuation levels and prices.

Other symbols: AXPCATCVXJNJKOWMT
3 weeks ago - InvestorPlace

AMGEN ANNOUNCES WEBCAST OF 2022 WELLS FARGO HEALTHCARE CONFERENCE

THOUSAND OAKS, Calif. , Sept. 2, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Wells Fargo's 2022 Global Healthcare Conference at 9:45 a.m.

4 weeks ago - PRNewsWire

AMGEN ANNOUNCES WEBCAST OF 2022 CITI GLOBAL HEALTHCARE CONFERENCE

THOUSAND OAKS, Calif. , Sept. 2, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2022 Global Healthcare Conference at 8:50 a.m.

4 weeks ago - PRNewsWire

Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5

The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.

1 month ago - Investors Business Daily

Amgen's (AMGN) Lumakras Meets Goal in New Lung Cancer Study

Amgen's (AMGN) phase III CodeBreaK 200 study evaluating once-daily oral, Lumakras, for treating KRAS G12C-mutated non-small cell lung cancer meets its primary endpoint.

1 month ago - Zacks Investment Research